Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Authors: Pfaller MA,Diekema DJ,International Fungal Surveillance Participant Group,
Address: Department of Pathology, Roy J. and Lucille A. Carver College of Medicine and College of Public Health, University of Iowa, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
Journal: Clin Microbiol Infect.

Publication: 2004 Mar;10 Suppl 1:11-23.

abstract

We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI) isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992 through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis, 153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, five C. rugosa, four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica, C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using the National Committee for clinical Laboratory Standards reference broth microdilution method. Variation in the rank order and frequency of the different species of Candida was observed over time and by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin America and the Asia-Pacific region. Very little variation in fluconazole susceptibility was observed among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI and remained highly susceptible (91-100% susceptible) to fluconazole from 1992 to 2001 irrespective of geographic origin. The prevalence of fluconazole resistance among C. glabrata isolates was variable both over time and among the various countries and regions. Resistance to fluconazole among C. glabrata isolates was greatest in the USA and varied by US census region (range 0-23%). These observations are generally encouraging relative to the sustained usefulness of fluconazole as a systemically active antifungal agent for the treatment of candida BSI.

Related Articles
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
J Clin Microbiol. 2001
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA, SENTRY Participant Group. J Clin Microbiol. 2001 Sep; 39(9):3254-9.
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.
J Clin Microbiol. 1998
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.
Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. J Clin Microbiol. 1998 Jul; 36(7):1886-9.
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.
Diagn Microbiol Infect Dis. 1999
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.
Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. Diagn Microbiol Infect Dis. 1999 Apr; 33(4):217-22.
Review Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
J Hosp Infect. 2002
Review Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V, Barnes AJ. J Hosp Infect. 2002 Apr; 50(4):243-60.
Review Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors.
J Infect Chemother. 2001
Review Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors.
Kovacicova G, Hanzen J, Pisarcikova M, Sejnova D, Horn J, Babela R, Svetlansky I, Lovaszova M, Gogova M, Krcmery V. J Infect Chemother. 2001 Mar; 7(1):45-8.
Molecular species identification of Candida from blood samples of intensive care unit patients by polymerase chain reaction - restricted fragment length polymorphism.
J Lab Physicians. 2012
Molecular species identification of Candida from blood samples of intensive care unit patients by polymerase chain reaction - restricted fragment length polymorphism.
Vijayakumar R, Giri S, Kindo AJ. J Lab Physicians. 2012 Jan; 4(1):1-4.
Amino acid-derived 1,2-benzisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets.
Antimicrob Agents Chemother. 2...
Amino acid-derived 1,2-benzisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets.
Alex D, Gay-Andrieu F, May J, Thampi L, Dou D, Mooney A, Groutas W, Calderone R. Antimicrob Agents Chemother. 2012 Sep; 56(9):4630-9. Epub 2012 Jun 11.
Upregulation of the ERG11 gene in Candida krusei by azoles.
Daru. 2010
Upregulation of the ERG11 gene in Candida krusei by azoles.
Tavakoli M, Zaini F, Kordbacheh M, Safara M, Raoofian R, Heidari M. Daru. 2010; 18(4):276-80.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.